nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ALB—atherosclerosis	0.182	1	CbGaD
Tacrolimus—ALB—Rosuvastatin—atherosclerosis	0.0437	0.0877	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0435	0.0873	CbGbCtD
Tacrolimus—CYP3A7—Simvastatin—atherosclerosis	0.0435	0.0873	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0426	0.0855	CbGbCtD
Tacrolimus—CYP3A7—Lovastatin—atherosclerosis	0.0426	0.0855	CbGbCtD
Tacrolimus—CYP3A5—Rosuvastatin—atherosclerosis	0.0351	0.0705	CbGbCtD
Tacrolimus—CYP3A5—Simvastatin—atherosclerosis	0.0326	0.0655	CbGbCtD
Tacrolimus—CYP3A5—Lovastatin—atherosclerosis	0.0319	0.0641	CbGbCtD
Tacrolimus—CYP3A5—Pravastatin—atherosclerosis	0.0319	0.0641	CbGbCtD
Tacrolimus—ABCB1—Ezetimibe—atherosclerosis	0.0229	0.0459	CbGbCtD
Tacrolimus—ABCB1—Simvastatin—atherosclerosis	0.0212	0.0426	CbGbCtD
Tacrolimus—ABCB1—Lovastatin—atherosclerosis	0.0208	0.0417	CbGbCtD
Tacrolimus—ABCB1—Pravastatin—atherosclerosis	0.0208	0.0417	CbGbCtD
Tacrolimus—CYP3A4—Ezetimibe—atherosclerosis	0.0137	0.0275	CbGbCtD
Tacrolimus—CYP3A4—Rosuvastatin—atherosclerosis	0.0137	0.0275	CbGbCtD
Tacrolimus—CYP3A4—Simvastatin—atherosclerosis	0.0127	0.0255	CbGbCtD
Tacrolimus—CYP3A4—Lovastatin—atherosclerosis	0.0125	0.025	CbGbCtD
Tacrolimus—CYP3A4—Pravastatin—atherosclerosis	0.0125	0.025	CbGbCtD
Tacrolimus—MTOR—leg—atherosclerosis	0.00602	0.15	CbGeAlD
Tacrolimus—MTOR—hindlimb—atherosclerosis	0.00537	0.134	CbGeAlD
Tacrolimus—MTOR—appendage—atherosclerosis	0.00461	0.115	CbGeAlD
Tacrolimus—MTOR—blood vessel—atherosclerosis	0.00257	0.0641	CbGeAlD
Tacrolimus—ABCA5—adipose tissue—atherosclerosis	0.00202	0.0506	CbGeAlD
Tacrolimus—PPP3CA—connective tissue—atherosclerosis	0.00178	0.0445	CbGeAlD
Tacrolimus—PPP3CA—cardiovascular system—atherosclerosis	0.00155	0.0387	CbGeAlD
Tacrolimus—ABCA5—liver—atherosclerosis	0.00142	0.0355	CbGeAlD
Tacrolimus—PPP3CA—adipose tissue—atherosclerosis	0.00137	0.0342	CbGeAlD
Tacrolimus—MTOR—connective tissue—atherosclerosis	0.00132	0.0329	CbGeAlD
Tacrolimus—FKBP1A—connective tissue—atherosclerosis	0.00118	0.0296	CbGeAlD
Tacrolimus—MTOR—cardiovascular system—atherosclerosis	0.00114	0.0286	CbGeAlD
Tacrolimus—FKBP1A—cardiovascular system—atherosclerosis	0.00103	0.0257	CbGeAlD
Tacrolimus—MTOR—adipose tissue—atherosclerosis	0.00101	0.0252	CbGeAlD
Tacrolimus—PPP3CA—liver—atherosclerosis	0.000958	0.024	CbGeAlD
Tacrolimus—FKBP1A—adipose tissue—atherosclerosis	0.000908	0.0227	CbGeAlD
Tacrolimus—CYP3A7—liver—atherosclerosis	0.000788	0.0197	CbGeAlD
Tacrolimus—MTOR—liver—atherosclerosis	0.000708	0.0177	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—liver—atherosclerosis	0.00067	0.0167	CbGeAlD
Tacrolimus—FKBP1A—liver—atherosclerosis	0.000637	0.0159	CbGeAlD
Tacrolimus—ABCB1—blood vessel—atherosclerosis	0.000534	0.0133	CbGeAlD
Tacrolimus—ORM1—liver—atherosclerosis	0.000499	0.0125	CbGeAlD
Tacrolimus—ALB—liver—atherosclerosis	0.000437	0.0109	CbGeAlD
Tacrolimus—CYP3A5—adipose tissue—atherosclerosis	0.000395	0.00988	CbGeAlD
Tacrolimus—CYP3A5—liver—atherosclerosis	0.000277	0.00693	CbGeAlD
Tacrolimus—ABCB1—cardiovascular system—atherosclerosis	0.000238	0.00595	CbGeAlD
Tacrolimus—Tinnitus—Pravastatin—atherosclerosis	0.000214	0.00131	CcSEcCtD
Tacrolimus—Malaise—Lovastatin—atherosclerosis	0.000213	0.0013	CcSEcCtD
Tacrolimus—Cardiac disorder—Pravastatin—atherosclerosis	0.000213	0.0013	CcSEcCtD
Tacrolimus—Flushing—Pravastatin—atherosclerosis	0.000213	0.0013	CcSEcCtD
Tacrolimus—Muscle spasms—Simvastatin—atherosclerosis	0.000212	0.0013	CcSEcCtD
Tacrolimus—Vertigo—Lovastatin—atherosclerosis	0.000212	0.0013	CcSEcCtD
Tacrolimus—Angiopathy—Niacin—atherosclerosis	0.000211	0.00129	CcSEcCtD
Tacrolimus—Leukopenia—Lovastatin—atherosclerosis	0.000211	0.00129	CcSEcCtD
Tacrolimus—ABCB1—adipose tissue—atherosclerosis	0.00021	0.00525	CbGeAlD
Tacrolimus—Chills—Niacin—atherosclerosis	0.000209	0.00128	CcSEcCtD
Tacrolimus—Malaise—Ezetimibe—atherosclerosis	0.000209	0.00128	CcSEcCtD
Tacrolimus—Vision blurred—Simvastatin—atherosclerosis	0.000208	0.00127	CcSEcCtD
Tacrolimus—Arrhythmia—Niacin—atherosclerosis	0.000208	0.00127	CcSEcCtD
Tacrolimus—CYP3A4—liver—atherosclerosis	0.000208	0.0052	CbGeAlD
Tacrolimus—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000207	0.00127	CcSEcCtD
Tacrolimus—Tremor—Simvastatin—atherosclerosis	0.000207	0.00126	CcSEcCtD
Tacrolimus—Alopecia—Niacin—atherosclerosis	0.000206	0.00126	CcSEcCtD
Tacrolimus—Chills—Pravastatin—atherosclerosis	0.000206	0.00126	CcSEcCtD
Tacrolimus—Insomnia—Rosuvastatin—atherosclerosis	0.000206	0.00126	CcSEcCtD
Tacrolimus—Ill-defined disorder—Simvastatin—atherosclerosis	0.000205	0.00125	CcSEcCtD
Tacrolimus—Arrhythmia—Pravastatin—atherosclerosis	0.000205	0.00125	CcSEcCtD
Tacrolimus—Palpitations—Ezetimibe—atherosclerosis	0.000205	0.00125	CcSEcCtD
Tacrolimus—Paraesthesia—Rosuvastatin—atherosclerosis	0.000204	0.00125	CcSEcCtD
Tacrolimus—Anaemia—Simvastatin—atherosclerosis	0.000204	0.00125	CcSEcCtD
Tacrolimus—Erythema—Niacin—atherosclerosis	0.000203	0.00124	CcSEcCtD
Tacrolimus—Malnutrition—Niacin—atherosclerosis	0.000203	0.00124	CcSEcCtD
Tacrolimus—Alopecia—Pravastatin—atherosclerosis	0.000203	0.00124	CcSEcCtD
Tacrolimus—Cough—Ezetimibe—atherosclerosis	0.000202	0.00123	CcSEcCtD
Tacrolimus—Arthralgia—Lovastatin—atherosclerosis	0.000201	0.00123	CcSEcCtD
Tacrolimus—Chest pain—Lovastatin—atherosclerosis	0.000201	0.00123	CcSEcCtD
Tacrolimus—Myalgia—Lovastatin—atherosclerosis	0.000201	0.00123	CcSEcCtD
Tacrolimus—Anxiety—Lovastatin—atherosclerosis	0.0002	0.00122	CcSEcCtD
Tacrolimus—Dyspepsia—Rosuvastatin—atherosclerosis	0.0002	0.00122	CcSEcCtD
Tacrolimus—Hypertension—Ezetimibe—atherosclerosis	0.0002	0.00122	CcSEcCtD
Tacrolimus—Flatulence—Niacin—atherosclerosis	0.0002	0.00122	CcSEcCtD
Tacrolimus—Malaise—Simvastatin—atherosclerosis	0.000199	0.00122	CcSEcCtD
Tacrolimus—Tension—Niacin—atherosclerosis	0.000199	0.00122	CcSEcCtD
Tacrolimus—Discomfort—Lovastatin—atherosclerosis	0.000199	0.00121	CcSEcCtD
Tacrolimus—Vertigo—Simvastatin—atherosclerosis	0.000198	0.00121	CcSEcCtD
Tacrolimus—Leukopenia—Simvastatin—atherosclerosis	0.000198	0.00121	CcSEcCtD
Tacrolimus—Chest pain—Ezetimibe—atherosclerosis	0.000197	0.0012	CcSEcCtD
Tacrolimus—Myalgia—Ezetimibe—atherosclerosis	0.000197	0.0012	CcSEcCtD
Tacrolimus—Arthralgia—Ezetimibe—atherosclerosis	0.000197	0.0012	CcSEcCtD
Tacrolimus—Nervousness—Niacin—atherosclerosis	0.000197	0.0012	CcSEcCtD
Tacrolimus—Flatulence—Pravastatin—atherosclerosis	0.000197	0.0012	CcSEcCtD
Tacrolimus—Dry mouth—Lovastatin—atherosclerosis	0.000197	0.0012	CcSEcCtD
Tacrolimus—Tension—Pravastatin—atherosclerosis	0.000196	0.0012	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000196	0.0012	CcSEcCtD
Tacrolimus—Dysgeusia—Pravastatin—atherosclerosis	0.000196	0.00119	CcSEcCtD
Tacrolimus—Muscle spasms—Niacin—atherosclerosis	0.000195	0.00119	CcSEcCtD
Tacrolimus—Discomfort—Ezetimibe—atherosclerosis	0.000195	0.00119	CcSEcCtD
Tacrolimus—Constipation—Rosuvastatin—atherosclerosis	0.000194	0.00119	CcSEcCtD
Tacrolimus—Pain—Rosuvastatin—atherosclerosis	0.000194	0.00119	CcSEcCtD
Tacrolimus—Confusional state—Lovastatin—atherosclerosis	0.000194	0.00119	CcSEcCtD
Tacrolimus—Nervousness—Pravastatin—atherosclerosis	0.000194	0.00118	CcSEcCtD
Tacrolimus—Dry mouth—Ezetimibe—atherosclerosis	0.000193	0.00118	CcSEcCtD
Tacrolimus—Anaphylactic shock—Lovastatin—atherosclerosis	0.000193	0.00118	CcSEcCtD
Tacrolimus—Muscle spasms—Pravastatin—atherosclerosis	0.000192	0.00117	CcSEcCtD
Tacrolimus—Infection—Lovastatin—atherosclerosis	0.000191	0.00117	CcSEcCtD
Tacrolimus—Vision blurred—Niacin—atherosclerosis	0.000191	0.00117	CcSEcCtD
Tacrolimus—Confusional state—Ezetimibe—atherosclerosis	0.000191	0.00116	CcSEcCtD
Tacrolimus—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000189	0.00115	CcSEcCtD
Tacrolimus—Thrombocytopenia—Lovastatin—atherosclerosis	0.000189	0.00115	CcSEcCtD
Tacrolimus—Vision blurred—Pravastatin—atherosclerosis	0.000188	0.00115	CcSEcCtD
Tacrolimus—Myalgia—Simvastatin—atherosclerosis	0.000188	0.00115	CcSEcCtD
Tacrolimus—Arthralgia—Simvastatin—atherosclerosis	0.000188	0.00115	CcSEcCtD
Tacrolimus—Chest pain—Simvastatin—atherosclerosis	0.000188	0.00115	CcSEcCtD
Tacrolimus—Infection—Ezetimibe—atherosclerosis	0.000188	0.00115	CcSEcCtD
Tacrolimus—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000187	0.00114	CcSEcCtD
Tacrolimus—Anxiety—Simvastatin—atherosclerosis	0.000187	0.00114	CcSEcCtD
Tacrolimus—Tremor—Pravastatin—atherosclerosis	0.000187	0.00114	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000186	0.00114	CcSEcCtD
Tacrolimus—Discomfort—Simvastatin—atherosclerosis	0.000186	0.00113	CcSEcCtD
Tacrolimus—Nervous system disorder—Ezetimibe—atherosclerosis	0.000185	0.00113	CcSEcCtD
Tacrolimus—Ill-defined disorder—Pravastatin—atherosclerosis	0.000185	0.00113	CcSEcCtD
Tacrolimus—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000185	0.00113	CcSEcCtD
Tacrolimus—Anaemia—Pravastatin—atherosclerosis	0.000185	0.00113	CcSEcCtD
Tacrolimus—Anorexia—Lovastatin—atherosclerosis	0.000184	0.00112	CcSEcCtD
Tacrolimus—Skin disorder—Ezetimibe—atherosclerosis	0.000184	0.00112	CcSEcCtD
Tacrolimus—Vertigo—Niacin—atherosclerosis	0.000182	0.00111	CcSEcCtD
Tacrolimus—Syncope—Niacin—atherosclerosis	0.000182	0.00111	CcSEcCtD
Tacrolimus—Confusional state—Simvastatin—atherosclerosis	0.000182	0.00111	CcSEcCtD
Tacrolimus—Leukopenia—Niacin—atherosclerosis	0.000182	0.00111	CcSEcCtD
Tacrolimus—Urticaria—Rosuvastatin—atherosclerosis	0.000181	0.0011	CcSEcCtD
Tacrolimus—Anaphylactic shock—Simvastatin—atherosclerosis	0.00018	0.0011	CcSEcCtD
Tacrolimus—Oedema—Simvastatin—atherosclerosis	0.00018	0.0011	CcSEcCtD
Tacrolimus—Malaise—Pravastatin—atherosclerosis	0.00018	0.0011	CcSEcCtD
Tacrolimus—Abdominal pain—Rosuvastatin—atherosclerosis	0.00018	0.0011	CcSEcCtD
Tacrolimus—Vertigo—Pravastatin—atherosclerosis	0.000179	0.0011	CcSEcCtD
Tacrolimus—Palpitations—Niacin—atherosclerosis	0.000179	0.00109	CcSEcCtD
Tacrolimus—Infection—Simvastatin—atherosclerosis	0.000179	0.00109	CcSEcCtD
Tacrolimus—Leukopenia—Pravastatin—atherosclerosis	0.000179	0.00109	CcSEcCtD
Tacrolimus—Loss of consciousness—Niacin—atherosclerosis	0.000178	0.00109	CcSEcCtD
Tacrolimus—Cough—Niacin—atherosclerosis	0.000177	0.00108	CcSEcCtD
Tacrolimus—Thrombocytopenia—Simvastatin—atherosclerosis	0.000177	0.00108	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000176	0.00107	CcSEcCtD
Tacrolimus—Insomnia—Lovastatin—atherosclerosis	0.000174	0.00106	CcSEcCtD
Tacrolimus—Cough—Pravastatin—atherosclerosis	0.000174	0.00106	CcSEcCtD
Tacrolimus—Paraesthesia—Lovastatin—atherosclerosis	0.000173	0.00106	CcSEcCtD
Tacrolimus—Arthralgia—Niacin—atherosclerosis	0.000173	0.00105	CcSEcCtD
Tacrolimus—Myalgia—Niacin—atherosclerosis	0.000173	0.00105	CcSEcCtD
Tacrolimus—Hypertension—Pravastatin—atherosclerosis	0.000172	0.00105	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000172	0.00105	CcSEcCtD
Tacrolimus—Anorexia—Simvastatin—atherosclerosis	0.000172	0.00105	CcSEcCtD
Tacrolimus—Dyspnoea—Lovastatin—atherosclerosis	0.000172	0.00105	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000171	0.00105	CcSEcCtD
Tacrolimus—Insomnia—Ezetimibe—atherosclerosis	0.000171	0.00104	CcSEcCtD
Tacrolimus—Chest pain—Pravastatin—atherosclerosis	0.00017	0.00104	CcSEcCtD
Tacrolimus—Arthralgia—Pravastatin—atherosclerosis	0.00017	0.00104	CcSEcCtD
Tacrolimus—Myalgia—Pravastatin—atherosclerosis	0.00017	0.00104	CcSEcCtD
Tacrolimus—Paraesthesia—Ezetimibe—atherosclerosis	0.00017	0.00104	CcSEcCtD
Tacrolimus—Dyspepsia—Lovastatin—atherosclerosis	0.00017	0.00104	CcSEcCtD
Tacrolimus—Anxiety—Pravastatin—atherosclerosis	0.000169	0.00103	CcSEcCtD
Tacrolimus—Dry mouth—Niacin—atherosclerosis	0.000169	0.00103	CcSEcCtD
Tacrolimus—Dyspnoea—Ezetimibe—atherosclerosis	0.000169	0.00103	CcSEcCtD
Tacrolimus—Discomfort—Pravastatin—atherosclerosis	0.000168	0.00103	CcSEcCtD
Tacrolimus—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000168	0.00102	CcSEcCtD
Tacrolimus—Decreased appetite—Lovastatin—atherosclerosis	0.000168	0.00102	CcSEcCtD
Tacrolimus—Dyspepsia—Ezetimibe—atherosclerosis	0.000166	0.00102	CcSEcCtD
Tacrolimus—Fatigue—Lovastatin—atherosclerosis	0.000166	0.00101	CcSEcCtD
Tacrolimus—Oedema—Niacin—atherosclerosis	0.000166	0.00101	CcSEcCtD
Tacrolimus—Anaphylactic shock—Niacin—atherosclerosis	0.000166	0.00101	CcSEcCtD
Tacrolimus—Constipation—Lovastatin—atherosclerosis	0.000165	0.00101	CcSEcCtD
Tacrolimus—Pain—Lovastatin—atherosclerosis	0.000165	0.00101	CcSEcCtD
Tacrolimus—Confusional state—Pravastatin—atherosclerosis	0.000164	0.001	CcSEcCtD
Tacrolimus—Decreased appetite—Ezetimibe—atherosclerosis	0.000164	0.001	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000164	0.001	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000163	0.000996	CcSEcCtD
Tacrolimus—Asthenia—Rosuvastatin—atherosclerosis	0.000163	0.000996	CcSEcCtD
Tacrolimus—Insomnia—Simvastatin—atherosclerosis	0.000163	0.000996	CcSEcCtD
Tacrolimus—Anaphylactic shock—Pravastatin—atherosclerosis	0.000163	0.000995	CcSEcCtD
Tacrolimus—Oedema—Pravastatin—atherosclerosis	0.000163	0.000995	CcSEcCtD
Tacrolimus—Fatigue—Ezetimibe—atherosclerosis	0.000163	0.000995	CcSEcCtD
Tacrolimus—Shock—Niacin—atherosclerosis	0.000163	0.000994	CcSEcCtD
Tacrolimus—Infection—Pravastatin—atherosclerosis	0.000162	0.000989	CcSEcCtD
Tacrolimus—Paraesthesia—Simvastatin—atherosclerosis	0.000162	0.000988	CcSEcCtD
Tacrolimus—Pain—Ezetimibe—atherosclerosis	0.000162	0.000987	CcSEcCtD
Tacrolimus—Constipation—Ezetimibe—atherosclerosis	0.000162	0.000987	CcSEcCtD
Tacrolimus—Tachycardia—Niacin—atherosclerosis	0.000162	0.000986	CcSEcCtD
Tacrolimus—Pruritus—Rosuvastatin—atherosclerosis	0.000161	0.000982	CcSEcCtD
Tacrolimus—Skin disorder—Niacin—atherosclerosis	0.000161	0.000982	CcSEcCtD
Tacrolimus—Dyspnoea—Simvastatin—atherosclerosis	0.000161	0.000981	CcSEcCtD
Tacrolimus—Hyperhidrosis—Niacin—atherosclerosis	0.00016	0.000977	CcSEcCtD
Tacrolimus—Thrombocytopenia—Pravastatin—atherosclerosis	0.00016	0.000974	CcSEcCtD
Tacrolimus—Feeling abnormal—Lovastatin—atherosclerosis	0.000159	0.00097	CcSEcCtD
Tacrolimus—Dyspepsia—Simvastatin—atherosclerosis	0.000159	0.000969	CcSEcCtD
Tacrolimus—Anorexia—Niacin—atherosclerosis	0.000158	0.000963	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000158	0.000962	CcSEcCtD
Tacrolimus—Hyperhidrosis—Pravastatin—atherosclerosis	0.000158	0.000962	CcSEcCtD
Tacrolimus—Decreased appetite—Simvastatin—atherosclerosis	0.000157	0.000957	CcSEcCtD
Tacrolimus—Feeling abnormal—Ezetimibe—atherosclerosis	0.000156	0.000951	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000156	0.00095	CcSEcCtD
Tacrolimus—Diarrhoea—Rosuvastatin—atherosclerosis	0.000156	0.00095	CcSEcCtD
Tacrolimus—Fatigue—Simvastatin—atherosclerosis	0.000155	0.000949	CcSEcCtD
Tacrolimus—Anorexia—Pravastatin—atherosclerosis	0.000155	0.000949	CcSEcCtD
Tacrolimus—Hypotension—Niacin—atherosclerosis	0.000155	0.000944	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000155	0.000944	CcSEcCtD
Tacrolimus—Pain—Simvastatin—atherosclerosis	0.000154	0.000941	CcSEcCtD
Tacrolimus—Constipation—Simvastatin—atherosclerosis	0.000154	0.000941	CcSEcCtD
Tacrolimus—Urticaria—Lovastatin—atherosclerosis	0.000153	0.000935	CcSEcCtD
Tacrolimus—Body temperature increased—Lovastatin—atherosclerosis	0.000152	0.00093	CcSEcCtD
Tacrolimus—Abdominal pain—Lovastatin—atherosclerosis	0.000152	0.00093	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000151	0.000921	CcSEcCtD
Tacrolimus—Dizziness—Rosuvastatin—atherosclerosis	0.00015	0.000918	CcSEcCtD
Tacrolimus—Urticaria—Ezetimibe—atherosclerosis	0.00015	0.000917	CcSEcCtD
Tacrolimus—Insomnia—Niacin—atherosclerosis	0.00015	0.000914	CcSEcCtD
Tacrolimus—Abdominal pain—Ezetimibe—atherosclerosis	0.000149	0.000912	CcSEcCtD
Tacrolimus—Body temperature increased—Ezetimibe—atherosclerosis	0.000149	0.000912	CcSEcCtD
Tacrolimus—Paraesthesia—Niacin—atherosclerosis	0.000149	0.000908	CcSEcCtD
Tacrolimus—Feeling abnormal—Simvastatin—atherosclerosis	0.000149	0.000907	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000148	0.000907	CcSEcCtD
Tacrolimus—Dyspnoea—Niacin—atherosclerosis	0.000148	0.000901	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000147	0.0009	CcSEcCtD
Tacrolimus—Insomnia—Pravastatin—atherosclerosis	0.000147	0.0009	CcSEcCtD
Tacrolimus—ABCB1—liver—atherosclerosis	0.000147	0.00368	CbGeAlD
Tacrolimus—Somnolence—Niacin—atherosclerosis	0.000147	0.000899	CcSEcCtD
Tacrolimus—Paraesthesia—Pravastatin—atherosclerosis	0.000146	0.000894	CcSEcCtD
Tacrolimus—Dyspepsia—Niacin—atherosclerosis	0.000146	0.00089	CcSEcCtD
Tacrolimus—Dyspnoea—Pravastatin—atherosclerosis	0.000145	0.000887	CcSEcCtD
Tacrolimus—Decreased appetite—Niacin—atherosclerosis	0.000144	0.000879	CcSEcCtD
Tacrolimus—Dyspepsia—Pravastatin—atherosclerosis	0.000143	0.000876	CcSEcCtD
Tacrolimus—Rash—Rosuvastatin—atherosclerosis	0.000143	0.000876	CcSEcCtD
Tacrolimus—Dermatitis—Rosuvastatin—atherosclerosis	0.000143	0.000875	CcSEcCtD
Tacrolimus—Urticaria—Simvastatin—atherosclerosis	0.000143	0.000874	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Niacin—atherosclerosis	0.000143	0.000873	CcSEcCtD
Tacrolimus—Abdominal pain—Simvastatin—atherosclerosis	0.000143	0.00087	CcSEcCtD
Tacrolimus—Body temperature increased—Simvastatin—atherosclerosis	0.000143	0.00087	CcSEcCtD
Tacrolimus—Headache—Rosuvastatin—atherosclerosis	0.000142	0.00087	CcSEcCtD
Tacrolimus—Hypersensitivity—Lovastatin—atherosclerosis	0.000142	0.000867	CcSEcCtD
Tacrolimus—Decreased appetite—Pravastatin—atherosclerosis	0.000142	0.000865	CcSEcCtD
Tacrolimus—Pain—Niacin—atherosclerosis	0.000142	0.000864	CcSEcCtD
Tacrolimus—Fatigue—Pravastatin—atherosclerosis	0.000141	0.000858	CcSEcCtD
Tacrolimus—Constipation—Pravastatin—atherosclerosis	0.000139	0.000851	CcSEcCtD
Tacrolimus—Pain—Pravastatin—atherosclerosis	0.000139	0.000851	CcSEcCtD
Tacrolimus—Hypersensitivity—Ezetimibe—atherosclerosis	0.000139	0.00085	CcSEcCtD
Tacrolimus—Asthenia—Lovastatin—atherosclerosis	0.000138	0.000844	CcSEcCtD
Tacrolimus—Pruritus—Lovastatin—atherosclerosis	0.000136	0.000833	CcSEcCtD
Tacrolimus—Asthenia—Ezetimibe—atherosclerosis	0.000136	0.000828	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Niacin—atherosclerosis	0.000135	0.000826	CcSEcCtD
Tacrolimus—Nausea—Rosuvastatin—atherosclerosis	0.000135	0.000825	CcSEcCtD
Tacrolimus—Feeling abnormal—Pravastatin—atherosclerosis	0.000134	0.00082	CcSEcCtD
Tacrolimus—Pruritus—Ezetimibe—atherosclerosis	0.000134	0.000817	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000133	0.000814	CcSEcCtD
Tacrolimus—Hypersensitivity—Simvastatin—atherosclerosis	0.000133	0.000811	CcSEcCtD
Tacrolimus—Diarrhoea—Lovastatin—atherosclerosis	0.000132	0.000805	CcSEcCtD
Tacrolimus—Urticaria—Niacin—atherosclerosis	0.000132	0.000803	CcSEcCtD
Tacrolimus—Abdominal pain—Niacin—atherosclerosis	0.000131	0.000799	CcSEcCtD
Tacrolimus—Body temperature increased—Niacin—atherosclerosis	0.000131	0.000799	CcSEcCtD
Tacrolimus—Urticaria—Pravastatin—atherosclerosis	0.000129	0.000791	CcSEcCtD
Tacrolimus—Asthenia—Simvastatin—atherosclerosis	0.000129	0.00079	CcSEcCtD
Tacrolimus—Diarrhoea—Ezetimibe—atherosclerosis	0.000129	0.00079	CcSEcCtD
Tacrolimus—Abdominal pain—Pravastatin—atherosclerosis	0.000129	0.000787	CcSEcCtD
Tacrolimus—Body temperature increased—Pravastatin—atherosclerosis	0.000129	0.000787	CcSEcCtD
Tacrolimus—Pruritus—Simvastatin—atherosclerosis	0.000128	0.000779	CcSEcCtD
Tacrolimus—Dizziness—Lovastatin—atherosclerosis	0.000127	0.000778	CcSEcCtD
Tacrolimus—Dizziness—Ezetimibe—atherosclerosis	0.000125	0.000763	CcSEcCtD
Tacrolimus—Diarrhoea—Simvastatin—atherosclerosis	0.000123	0.000753	CcSEcCtD
Tacrolimus—Vomiting—Lovastatin—atherosclerosis	0.000123	0.000748	CcSEcCtD
Tacrolimus—Hypersensitivity—Niacin—atherosclerosis	0.000122	0.000745	CcSEcCtD
Tacrolimus—Rash—Lovastatin—atherosclerosis	0.000122	0.000742	CcSEcCtD
Tacrolimus—Dermatitis—Lovastatin—atherosclerosis	0.000121	0.000741	CcSEcCtD
Tacrolimus—Headache—Lovastatin—atherosclerosis	0.000121	0.000737	CcSEcCtD
Tacrolimus—Vomiting—Ezetimibe—atherosclerosis	0.00012	0.000734	CcSEcCtD
Tacrolimus—Hypersensitivity—Pravastatin—atherosclerosis	0.00012	0.000733	CcSEcCtD
Tacrolimus—Dizziness—Simvastatin—atherosclerosis	0.000119	0.000728	CcSEcCtD
Tacrolimus—Rash—Ezetimibe—atherosclerosis	0.000119	0.000728	CcSEcCtD
Tacrolimus—Dermatitis—Ezetimibe—atherosclerosis	0.000119	0.000727	CcSEcCtD
Tacrolimus—Asthenia—Niacin—atherosclerosis	0.000119	0.000725	CcSEcCtD
Tacrolimus—Headache—Ezetimibe—atherosclerosis	0.000118	0.000723	CcSEcCtD
Tacrolimus—Pruritus—Niacin—atherosclerosis	0.000117	0.000715	CcSEcCtD
Tacrolimus—Asthenia—Pravastatin—atherosclerosis	0.000117	0.000714	CcSEcCtD
Tacrolimus—Pruritus—Pravastatin—atherosclerosis	0.000115	0.000704	CcSEcCtD
Tacrolimus—Vomiting—Simvastatin—atherosclerosis	0.000115	0.0007	CcSEcCtD
Tacrolimus—Nausea—Lovastatin—atherosclerosis	0.000114	0.000699	CcSEcCtD
Tacrolimus—Rash—Simvastatin—atherosclerosis	0.000114	0.000694	CcSEcCtD
Tacrolimus—Dermatitis—Simvastatin—atherosclerosis	0.000114	0.000693	CcSEcCtD
Tacrolimus—Diarrhoea—Niacin—atherosclerosis	0.000113	0.000692	CcSEcCtD
Tacrolimus—Headache—Simvastatin—atherosclerosis	0.000113	0.00069	CcSEcCtD
Tacrolimus—Nausea—Ezetimibe—atherosclerosis	0.000112	0.000686	CcSEcCtD
Tacrolimus—Diarrhoea—Pravastatin—atherosclerosis	0.000112	0.000681	CcSEcCtD
Tacrolimus—Dizziness—Niacin—atherosclerosis	0.000109	0.000668	CcSEcCtD
Tacrolimus—Dizziness—Pravastatin—atherosclerosis	0.000108	0.000658	CcSEcCtD
Tacrolimus—Nausea—Simvastatin—atherosclerosis	0.000107	0.000654	CcSEcCtD
Tacrolimus—Vomiting—Niacin—atherosclerosis	0.000105	0.000643	CcSEcCtD
Tacrolimus—Rash—Niacin—atherosclerosis	0.000104	0.000637	CcSEcCtD
Tacrolimus—Dermatitis—Niacin—atherosclerosis	0.000104	0.000637	CcSEcCtD
Tacrolimus—Headache—Niacin—atherosclerosis	0.000104	0.000633	CcSEcCtD
Tacrolimus—Vomiting—Pravastatin—atherosclerosis	0.000104	0.000633	CcSEcCtD
Tacrolimus—Rash—Pravastatin—atherosclerosis	0.000103	0.000627	CcSEcCtD
Tacrolimus—Dermatitis—Pravastatin—atherosclerosis	0.000103	0.000627	CcSEcCtD
Tacrolimus—Headache—Pravastatin—atherosclerosis	0.000102	0.000623	CcSEcCtD
Tacrolimus—Nausea—Niacin—atherosclerosis	9.83e-05	0.0006	CcSEcCtD
Tacrolimus—Nausea—Pravastatin—atherosclerosis	9.68e-05	0.000591	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—APOA2—atherosclerosis	1.1e-05	9.5e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALOX5AP—atherosclerosis	1.1e-05	9.5e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALOX15—atherosclerosis	1.1e-05	9.5e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOC3—atherosclerosis	1.1e-05	9.48e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL6—atherosclerosis	1.09e-05	9.47e-05	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.09e-05	9.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.09e-05	9.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—LDLR—atherosclerosis	1.09e-05	9.43e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ABCG5—atherosclerosis	1.08e-05	9.39e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CG—atherosclerosis	1.08e-05	9.36e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.08e-05	9.35e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.08e-05	9.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.08e-05	9.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.08e-05	9.32e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MAPK3—atherosclerosis	1.07e-05	9.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP3—atherosclerosis	1.07e-05	9.25e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ALOX5—atherosclerosis	1.07e-05	9.22e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF2—atherosclerosis	1.06e-05	9.21e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CETP—atherosclerosis	1.06e-05	9.21e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.06e-05	9.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—LPA—atherosclerosis	1.05e-05	9.07e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFB1—atherosclerosis	1.04e-05	9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOB—atherosclerosis	1.03e-05	8.94e-05	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.03e-05	8.87e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—atherosclerosis	1.02e-05	8.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SCARB1—atherosclerosis	1.02e-05	8.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—HMOX1—atherosclerosis	1.02e-05	8.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EDN1—atherosclerosis	1.02e-05	8.8e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—BGN—atherosclerosis	1.01e-05	8.78e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—atherosclerosis	1.01e-05	8.77e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—atherosclerosis	1.01e-05	8.75e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—atherosclerosis	1.01e-05	8.74e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL5—atherosclerosis	1.01e-05	8.73e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—INS—atherosclerosis	1.01e-05	8.73e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOA5—atherosclerosis	1e-05	8.69e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IGF1—atherosclerosis	9.9e-06	8.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—LPL—atherosclerosis	9.86e-06	8.54e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	9.84e-06	8.52e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL8—atherosclerosis	9.77e-06	8.45e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOB—atherosclerosis	9.75e-06	8.44e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MAPK3—atherosclerosis	9.68e-06	8.38e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PLA2G1B—atherosclerosis	9.67e-06	8.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HMGCR—atherosclerosis	9.62e-06	8.33e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PRKCG—atherosclerosis	9.59e-06	8.3e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	9.58e-06	8.29e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NAMPT—atherosclerosis	9.56e-06	8.27e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	9.5e-06	8.22e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—LIPC—atherosclerosis	9.5e-06	8.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTM1—atherosclerosis	9.48e-06	8.21e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOC3—atherosclerosis	9.44e-06	8.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SERPINE1—atherosclerosis	9.4e-06	8.14e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFB1—atherosclerosis	9.39e-06	8.13e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—LDLR—atherosclerosis	9.38e-06	8.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SPP1—atherosclerosis	9.34e-06	8.08e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALOX5—atherosclerosis	9.33e-06	8.08e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—atherosclerosis	9.32e-06	8.07e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—LPL—atherosclerosis	9.31e-06	8.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SERPINE1—atherosclerosis	9.26e-06	8.02e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CETP—atherosclerosis	9.16e-06	7.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—atherosclerosis	9.14e-06	7.91e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GPX1—atherosclerosis	9.08e-06	7.86e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	8.98e-06	7.77e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NOS3—atherosclerosis	8.98e-06	7.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CD36—atherosclerosis	8.84e-06	7.66e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOS3—atherosclerosis	8.84e-06	7.65e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—atherosclerosis	8.83e-06	7.65e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SCARB1—atherosclerosis	8.77e-06	7.59e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NFKB1—atherosclerosis	8.74e-06	7.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PDGFB—atherosclerosis	8.64e-06	7.48e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK8—atherosclerosis	8.59e-06	7.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ABCA1—atherosclerosis	8.57e-06	7.42e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCG1—atherosclerosis	8.51e-06	7.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AGT—atherosclerosis	8.44e-06	7.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MTHFR—atherosclerosis	8.38e-06	7.25e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NAMPT—atherosclerosis	8.37e-06	7.25e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—LIPC—atherosclerosis	8.32e-06	7.2e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HMGCR—atherosclerosis	8.29e-06	7.17e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOC3—atherosclerosis	8.27e-06	7.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOE—atherosclerosis	8.27e-06	7.15e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—LEP—atherosclerosis	8.27e-06	7.15e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARA—atherosclerosis	8.22e-06	7.12e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—LDLR—atherosclerosis	8.22e-06	7.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—atherosclerosis	8.19e-06	7.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CAV1—atherosclerosis	8.19e-06	7.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOA1—atherosclerosis	8.17e-06	7.07e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1B—atherosclerosis	8.15e-06	7.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—atherosclerosis	8.09e-06	7e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CETP—atherosclerosis	8.03e-06	6.95e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—FABP4—atherosclerosis	8e-06	6.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LCAT—atherosclerosis	8e-06	6.93e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	8e-06	6.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AGT—atherosclerosis	7.96e-06	6.89e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—atherosclerosis	7.93e-06	6.87e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ESR1—atherosclerosis	7.89e-06	6.83e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	7.88e-06	6.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOA4—atherosclerosis	7.86e-06	6.8e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—atherosclerosis	7.85e-06	6.8e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—atherosclerosis	7.83e-06	6.78e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOE—atherosclerosis	7.8e-06	6.75e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—F2—atherosclerosis	7.8e-06	6.75e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CAV1—atherosclerosis	7.73e-06	6.69e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP7A1—atherosclerosis	7.72e-06	6.68e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOA1—atherosclerosis	7.71e-06	6.68e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SCARB1—atherosclerosis	7.69e-06	6.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NFKB1—atherosclerosis	7.6e-06	6.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—atherosclerosis	7.56e-06	6.54e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK3—atherosclerosis	7.5e-06	6.5e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK8—atherosclerosis	7.47e-06	6.47e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.47e-06	6.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CG—atherosclerosis	7.46e-06	6.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ABCA1—atherosclerosis	7.38e-06	6.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HMOX1—atherosclerosis	7.36e-06	6.37e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—atherosclerosis	7.28e-06	6.3e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HMGCR—atherosclerosis	7.26e-06	6.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—atherosclerosis	7.26e-06	6.28e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—atherosclerosis	7.23e-06	6.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP27A1—atherosclerosis	7.13e-06	6.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	7.12e-06	6.16e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—atherosclerosis	7.08e-06	6.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—INS—atherosclerosis	7.06e-06	6.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOB—atherosclerosis	7.05e-06	6.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CG—atherosclerosis	7.04e-06	6.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL2—atherosclerosis	6.95e-06	6.01e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTM1—atherosclerosis	6.85e-06	5.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—atherosclerosis	6.83e-06	5.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1—atherosclerosis	6.83e-06	5.91e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—atherosclerosis	6.8e-06	5.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOA2—atherosclerosis	6.76e-06	5.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	6.76e-06	5.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	6.76e-06	5.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALOX15—atherosclerosis	6.76e-06	5.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—LPL—atherosclerosis	6.73e-06	5.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCG5—atherosclerosis	6.68e-06	5.78e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—INS—atherosclerosis	6.67e-06	5.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GPX1—atherosclerosis	6.56e-06	5.68e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—atherosclerosis	6.53e-06	5.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK3—atherosclerosis	6.53e-06	5.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SERPINE1—atherosclerosis	6.49e-06	5.61e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ABCA1—atherosclerosis	6.47e-06	5.6e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—atherosclerosis	6.47e-06	5.6e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LPA—atherosclerosis	6.45e-06	5.59e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CD36—atherosclerosis	6.39e-06	5.53e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HMOX1—atherosclerosis	6.34e-06	5.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—atherosclerosis	6.31e-06	5.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—BGN—atherosclerosis	6.25e-06	5.41e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOS3—atherosclerosis	6.19e-06	5.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOA5—atherosclerosis	6.19e-06	5.35e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—MAPK3—atherosclerosis	6.12e-06	5.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—atherosclerosis	6.11e-06	5.29e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOB—atherosclerosis	6.07e-06	5.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTHFR—atherosclerosis	6.06e-06	5.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAPK3—atherosclerosis	6.03e-06	5.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	5.95e-06	5.15e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARA—atherosclerosis	5.94e-06	5.14e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—atherosclerosis	5.93e-06	5.14e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTM1—atherosclerosis	5.9e-06	5.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—atherosclerosis	5.85e-06	5.06e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NOS3—atherosclerosis	5.85e-06	5.06e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—LPL—atherosclerosis	5.79e-06	5.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AGT—atherosclerosis	5.76e-06	4.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALOX5—atherosclerosis	5.75e-06	4.98e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GPX1—atherosclerosis	5.65e-06	4.89e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOE—atherosclerosis	5.64e-06	4.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CAV1—atherosclerosis	5.59e-06	4.84e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOA1—atherosclerosis	5.58e-06	4.83e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HMOX1—atherosclerosis	5.55e-06	4.8e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CD36—atherosclerosis	5.51e-06	4.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—atherosclerosis	5.49e-06	4.75e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—atherosclerosis	5.49e-06	4.75e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—atherosclerosis	5.35e-06	4.63e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOB—atherosclerosis	5.32e-06	4.6e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTHFR—atherosclerosis	5.22e-06	4.52e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTM1—atherosclerosis	5.17e-06	4.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.16e-06	4.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LIPC—atherosclerosis	5.13e-06	4.44e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARA—atherosclerosis	5.12e-06	4.43e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOC3—atherosclerosis	5.09e-06	4.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CG—atherosclerosis	5.09e-06	4.41e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—LPL—atherosclerosis	5.08e-06	4.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LDLR—atherosclerosis	5.06e-06	4.38e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—atherosclerosis	5.06e-06	4.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—atherosclerosis	4.97e-06	4.3e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AGT—atherosclerosis	4.96e-06	4.29e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GPX1—atherosclerosis	4.95e-06	4.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CETP—atherosclerosis	4.95e-06	4.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NFKB1—atherosclerosis	4.92e-06	4.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—atherosclerosis	4.91e-06	4.25e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOE—atherosclerosis	4.86e-06	4.2e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK8—atherosclerosis	4.83e-06	4.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CD36—atherosclerosis	4.82e-06	4.18e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—INS—atherosclerosis	4.82e-06	4.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CAV1—atherosclerosis	4.81e-06	4.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOA1—atherosclerosis	4.8e-06	4.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—atherosclerosis	4.77e-06	4.13e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.74e-06	4.1e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTHFR—atherosclerosis	4.57e-06	3.96e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARA—atherosclerosis	4.48e-06	3.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.47e-06	3.87e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—atherosclerosis	4.46e-06	3.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—atherosclerosis	4.42e-06	3.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—atherosclerosis	4.42e-06	3.82e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—atherosclerosis	4.41e-06	3.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—atherosclerosis	4.4e-06	3.81e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CG—atherosclerosis	4.38e-06	3.79e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AGT—atherosclerosis	4.34e-06	3.76e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOE—atherosclerosis	4.26e-06	3.68e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—atherosclerosis	4.23e-06	3.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NOS3—atherosclerosis	4.23e-06	3.66e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK3—atherosclerosis	4.22e-06	3.65e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CAV1—atherosclerosis	4.22e-06	3.65e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOA1—atherosclerosis	4.21e-06	3.64e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—INS—atherosclerosis	4.15e-06	3.59e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—atherosclerosis	4.13e-06	3.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—atherosclerosis	4.09e-06	3.54e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—atherosclerosis	4.07e-06	3.52e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.99e-06	3.45e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—atherosclerosis	3.86e-06	3.34e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CG—atherosclerosis	3.84e-06	3.32e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—atherosclerosis	3.71e-06	3.21e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NOS3—atherosclerosis	3.64e-06	3.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—INS—atherosclerosis	3.64e-06	3.15e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.42e-06	2.96e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—atherosclerosis	3.33e-06	2.89e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—atherosclerosis	3.33e-06	2.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOB—atherosclerosis	3.28e-06	2.84e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NOS3—atherosclerosis	3.19e-06	2.76e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.19e-06	2.76e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LPL—atherosclerosis	3.13e-06	2.71e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—atherosclerosis	3.09e-06	2.67e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPX1—atherosclerosis	3.05e-06	2.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CD36—atherosclerosis	2.97e-06	2.57e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—atherosclerosis	2.92e-06	2.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—atherosclerosis	2.85e-06	2.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.82e-06	2.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARA—atherosclerosis	2.76e-06	2.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—atherosclerosis	2.69e-06	2.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AGT—atherosclerosis	2.68e-06	2.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOE—atherosclerosis	2.62e-06	2.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CAV1—atherosclerosis	2.6e-06	2.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOA1—atherosclerosis	2.59e-06	2.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.37e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—atherosclerosis	2.28e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—INS—atherosclerosis	2.24e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—atherosclerosis	2.05e-06	1.78e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NOS3—atherosclerosis	1.96e-06	1.7e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—atherosclerosis	1.94e-06	1.68e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.8e-06	1.56e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—atherosclerosis	1.67e-06	1.45e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—atherosclerosis	1.47e-06	1.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—atherosclerosis	9.03e-07	7.82e-06	CbGpPWpGaD
